Clinical Trials
25 trialsNCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NCT05795595 2025-11-26
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Phase 1/2 Completed
NCT04180215 2025-09-15
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
Hookipa Biotech GmbH
Phase 1/2 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT04815720 2025-01-08
KEYNOTE-B84
Vaccinex Inc.
Phase 1/2 Completed
NCT03941873 2024-10-26
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
BeiGene
Phase 1/2 Completed
NCT01581840 2024-07-01
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed
NCT02705105 2024-04-25
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT00946881 2024-02-07
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 1/2 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT02898116 2022-10-10
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01592721 2022-09-21
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT03268057 2022-05-02
CLASSICAL-Lung
Vaccinex Inc.
Phase 1/2 Completed
NCT03633110 2022-04-19
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
Phase 1/2 Completed
NCT01554371 2021-02-03
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Completed
NCT00946153 2019-02-01
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Eisai Inc.
Phase 1/2 Completed
NCT01139775 2018-05-18
A Study in Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00510250 2015-07-27
A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00073736 2011-08-12
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
Ligand Pharmaceuticals
Phase 1/2 Completed
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed